These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
194 related articles for article (PubMed ID: 9615757)
1. Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (L-MTP-PE): a randomized clinical trial in dogs with mammary carcinoma. Teske E; Rutteman GR; vd Ingh TS; van Noort R; Misdorp W Anticancer Res; 1998; 18(2A):1015-9. PubMed ID: 9615757 [TBL] [Abstract][Full Text] [Related]
2. Adjuvant therapy for melanoma in dogs: results of randomized clinical trials using surgery, liposome-encapsulated muramyl tripeptide, and granulocyte macrophage colony-stimulating factor. MacEwen EG; Kurzman ID; Vail DM; Dubielzig RR; Everlith K; Madewell BR; Rodriguez CO; Phillips B; Zwahlen CH; Obradovich J; Rosenthal RC; Fox LE; Rosenberg M; Henry C; Fidel J Clin Cancer Res; 1999 Dec; 5(12):4249-58. PubMed ID: 10632367 [TBL] [Abstract][Full Text] [Related]
3. Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine adjuvant immunotherapy for splenic hemangiosarcoma in the dog: a randomized multi-institutional clinical trial. Vail DM; MacEwen EG; Kurzman ID; Dubielzig RR; Helfand SC; Kisseberth WC; London CA; Obradovich JE; Madewell BR; Rodriguez CO Clin Cancer Res; 1995 Oct; 1(10):1165-70. PubMed ID: 9815908 [TBL] [Abstract][Full Text] [Related]
4. Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma. Kleinerman ES; Gano JB; Johnston DA; Benjamin RS; Jaffe N Am J Clin Oncol; 1995 Apr; 18(2):93-9. PubMed ID: 7900714 [TBL] [Abstract][Full Text] [Related]
5. Combination therapy with ifosfamide and liposome-encapsulated muramyl tripeptide: tolerability, toxicity, and immune stimulation. Kleinerman ES; Meyers PA; Raymond AK; Gano JB; Jia SF; Jaffe N J Immunother Emphasis Tumor Immunol; 1995 Apr; 17(3):181-93. PubMed ID: 7613644 [TBL] [Abstract][Full Text] [Related]
6. Adjuvant therapy for osteosarcoma in dogs: results of randomized clinical trials using combined liposome-encapsulated muramyl tripeptide and cisplatin. Kurzman ID; MacEwen EG; Rosenthal RC; Fox LE; Keller ET; Helfand SC; Vail DM; Dubielzig RR; Madewell BR; Rodriguez CO Clin Cancer Res; 1995 Dec; 1(12):1595-601. PubMed ID: 9815961 [TBL] [Abstract][Full Text] [Related]
8. Current studies of liposome muramyl tripeptide (CGP 19835A lipid) therapy for metastasis in spontaneous tumors: a progress review. MacEwen EG; Kurzman ID; Helfand S; Vail D; London C; Kisseberth W; Rosenthal RC; Fox LE; Keller ET; Obradovich J J Drug Target; 1994; 2(5):391-6. PubMed ID: 7704483 [TBL] [Abstract][Full Text] [Related]
9. Therapy for osteosarcoma in dogs with intravenous injection of liposome-encapsulated muramyl tripeptide. MacEwen EG; Kurzman ID; Rosenthal RC; Smith BW; Manley PA; Roush JK; Howard PE J Natl Cancer Inst; 1989 Jun; 81(12):935-8. PubMed ID: 2733037 [TBL] [Abstract][Full Text] [Related]
10. Liposome-encapsulated MTP-PE: a novel biologic agent for cancer therapy. Asano T; Kleinerman ES J Immunother Emphasis Tumor Immunol; 1993 Nov; 14(4):286-92. PubMed ID: 8280710 [TBL] [Abstract][Full Text] [Related]
11. Effect of ibuprofen on monocyte activation by liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (CGP 19835A): can ibuprofen reduce fever and chills without compromising immune stimulation? Fujimaki W; Griffin JR; Kleinerman ES Cancer Immunol Immunother; 1993; 36(1):45-51. PubMed ID: 8422667 [TBL] [Abstract][Full Text] [Related]
12. Phase I trial of liposomal muramyl tripeptide phosphatidylethanolamine in cancer patients. Murray JL; Kleinerman ES; Cunningham JE; Tatom JR; Andrejcio K; Lepe-Zuniga J; Lamki LM; Rosenblum MG; Frost H; Gutterman JU J Clin Oncol; 1989 Dec; 7(12):1915-25. PubMed ID: 2479721 [TBL] [Abstract][Full Text] [Related]
13. Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide. Kleinerman ES Hematol Oncol Clin North Am; 1995 Aug; 9(4):927-38. PubMed ID: 7490249 [TBL] [Abstract][Full Text] [Related]
14. Comparative pharmacokinetics of free muramyl tripeptide phosphatidyl ethanolamine (MTP-PE) and liposomal MTP-PE. Gay B; Cardot JM; Schnell C; van Hoogevest P; Gygax D J Pharm Sci; 1993 Oct; 82(10):997-1001. PubMed ID: 8254500 [TBL] [Abstract][Full Text] [Related]
15. Intravesical liposomal muramyl tripeptide phosphatidylethanolamine treatment of human bladder carcinoma growing in nude mice. Dinney CP; Tanguay S; Bucana CD; Eve BY; Fidler IJ J Interferon Cytokine Res; 1995 Jun; 15(6):585-92. PubMed ID: 7553228 [TBL] [Abstract][Full Text] [Related]
16. Muramyl tripeptide phosphatidylethanolamine encapsulated in liposomes stimulates monocyte production of tumor necrosis factor and interleukin-1 in vitro. Maeda M; Knowles RD; Kleinerman ES Cancer Commun; 1991; 3(10-11):313-21. PubMed ID: 1722107 [TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo effect of doxorubicin combined with liposome-encapsulated muramyl tripeptide on canine monocyte activation. Shi F; MacEwen EG; Kurzman ID Cancer Res; 1993 Sep; 53(17):3986-91. PubMed ID: 8358727 [TBL] [Abstract][Full Text] [Related]
18. Therapy of human ovarian cancer xenografts with intraperitoneal liposome encapsulated muramyl-tripeptide phosphoethanolamine (MTP-PE) and recombinant GM-CSF. Malik ST; Martin D; Hart I; Balkwill F Br J Cancer; 1991 Mar; 63(3):399-403. PubMed ID: 2003980 [TBL] [Abstract][Full Text] [Related]
19. Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration. Kleinerman ES; Jia SF; Griffin J; Seibel NL; Benjamin RS; Jaffe N J Clin Oncol; 1992 Aug; 10(8):1310-6. PubMed ID: 1634921 [TBL] [Abstract][Full Text] [Related]
20. Induction of serum tumor necrosis factor-alpha and interleukin-6 activity by liposome-encapsulated muramyl tripeptide-phosphatidylethanolamine (L-MTP-PE) in normal cats. Fox LE; King RR; Shi F; Kurzman ID; MacEwen EG; Kubilis PS Cancer Biother; 1994; 9(4):329-40. PubMed ID: 7719380 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]